|
gptkbp:instanceOf
|
antifungal medication
triazole antifungal
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J02AC03
|
|
gptkbp:availableOn
|
gptkb:tablet
intravenous infusion
oral suspension
|
|
gptkbp:bioavailability
|
96% (oral)
|
|
gptkbp:brand
|
gptkb:Vfend
|
|
gptkbp:CASNumber
|
gptkb:137234-62-9
|
|
gptkbp:category
|
gptkb:essential_medicine_(WHO)
|
|
gptkbp:chemicalFormula
|
gptkb:C16H14F3N5O
|
|
gptkbp:contraindication
|
co-administration with certain drugs (e.g., rifampin, carbamazepine)
hypersensitivity to azoles
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer
|
|
gptkbp:drugClass
|
antifungal
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine (as metabolites)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Voriconazole
|
|
gptkbp:interactsWith
|
gptkb:sirolimus
gptkb:efavirenz
gptkb:cyclosporine
gptkb:phenytoin
gptkb:rifampin
gptkb:warfarin
gptkb:carbamazepine
gptkb:St._John's_Wort
statins
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
inhibits fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase
|
|
gptkbp:metabolism
|
liver
N-oxide metabolite
|
|
gptkbp:molecularWeight
|
349.3 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
58%
|
|
gptkbp:riskFactor
|
QT prolongation
hepatotoxicity
photosensitivity
teratogenicity
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
hallucinations
skin rash
visual disturbances
liver enzyme elevation
|
|
gptkbp:usedFor
|
treatment of invasive aspergillosis
treatment of candidemia
treatment of serious fungal infections
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|